{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:50:07Z","timestamp":1790826607932,"version":"4.1.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"DOI":"10.3389\/fped.2019.00159","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T02:45:12Z","timestamp":1583721912000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Tuberculosis and HIV\u2014An Update on the \u201cCursed Duet\u201d in Children"],"prefix":"10.3389","volume":"7","author":[{"given":"Samantha H.-L.","family":"Fry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun L.","family":"Barnabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.rmed.2006.08.006","article-title":"The history of tuberculosis","volume":"100","author":"Daniel","year":"2006","journal-title":"Respir Med."},{"key":"B2","year":"2017","journal-title":"Global Tuberculosis Report 2017"},{"key":"B3","year":"2018","journal-title":"Global Tuberculosis Report 2018"},{"key":"B4","first-page":"250","article-title":"Pneumocystis pneumonia\u2014Los Angeles","volume":"30","year":"1981","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B5","first-page":"665","article-title":"Unexplained immunodeficiency and opportunistic infections in infants\u2013New York, New Jersey, California","volume":"31","year":"1982","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B6","first-page":"868","article-title":"Isolation of a T-Lymphotropic Retrovirus from a patient at risk for acquired immune deficiency syndrome","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Am Assoc Adv Sci."},{"key":"B7","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1986.03370230061031","article-title":"Surveillance for aids in a central african city: Kinshasa, zaire","volume":"255","author":"Mann","year":"1986","journal-title":"JAMA."},{"key":"B8","first-page":"25","article-title":"Tuberculosis and HIV. The cursed duet","volume":"65","author":"Chretien","year":"1990","journal-title":"Bull Int Union Tuberc Lung Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1471-2334-14-S1-S5","article-title":"Tuberculosis and HIV co-infection in children","volume":"14","author":"Venturini","year":"2014","journal-title":"BMC Infect Dis."},{"key":"B10","unstructured":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00042560-199504000-00010","article-title":"CD4+ lymphocyte count in African patients co-infected with HIV and tuberculosis","volume":"8","author":"Martin","year":"1995","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/COH.0b013e3283524e32","article-title":"Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis","volume":"7","author":"Geldmacher","year":"2012","journal-title":"Curr Opin HIV AIDS."},{"key":"B13","first-page":"448","article-title":"HIV-1 co-infection in children hospitalised with tuberculosis in South Africa","volume":"4","author":"Madhi","year":"2000","journal-title":"Int J Tuberc Lung Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5588\/pha.15.0027","article-title":"HIV-TB co-infection in children: associated factors and access to HIV services in Lagos, Nigeria","volume":"5","author":"Daniel","year":"2015","journal-title":"Public Heal Action."},{"key":"B15","first-page":"672","article-title":"Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa","volume":"6","author":"Jeena","year":"2002","journal-title":"Int J Tuberc Lung Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/INF.0b013e318243e27b","article-title":"A proposed comprehensive classification of tuberculosis disease severity in children","volume":"31","author":"Wiseman","year":"2012","journal-title":"Pediatr Infect Dis J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4102\/sajhivmed.v19i1.701","article-title":"Reflections on a decade of delivering PMTCT in Khayelitsha, South Africa","volume":"14","author":"Stinson","year":"2013","journal-title":"South Africa J HIV Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.7196\/SAMJ.2018.v108i3.12817","article-title":"Closing the gaps to eliminate mother-to-child transmission of HIV (MTCT) in South Africa: understanding MTCT case rates, factors that hinder the monitoring and attainment of targets, and potential game changers","volume":"108","author":"Goga","year":"2018","journal-title":"Samj South African Med J."},{"key":"B19","first-page":"27","article-title":"Highest risk of mother to child transmission of HIV or death in the first 6 months postpartum: results from 18 month follow-up of an HIV-exposed national cohort, South Africa","volume":"19","author":"Goga","year":"2016","journal-title":"J Int AIDS Soc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/QAD.0000000000000794","article-title":"Delayed HIV detection among infants exposed to postnatal antiretroviral prophylaxis during breastfeeding","volume":"29","author":"King","year":"2015","journal-title":"AIDS."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1097\/QAD.0000000000000796","article-title":"Time of HIV diagnosis in infants after weaning from breast milk","volume":"29","author":"Kourtis","year":"2015","journal-title":"AIDS."},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cei.12251","article-title":"HIV-exposed uninfected children: a growing population with a vulnerable immune system?","volume":"176","author":"Afran","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e47337","DOI":"10.1371\/journal.pone.0047337","article-title":"Mortality and health outcomes of HIV-exposed and unexposed children in a PMTCT cohort in Malawi","volume":"7","author":"Landes","year":"2012","journal-title":"PLoS ONE."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/cid\/ciy673","article-title":"Initiation of anti-retroviral therapy before pregnancy reduces the risk of infection-related hospitalization in HIV-exposed uninfected infants born in a high-income country","volume":"68","author":"Goetghebuer","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/INF.0000000000001062","article-title":"Tuberculosis infection in early childhood and the association with HIV-exposure in HIV-uninfected children in rural Uganda","volume":"35","author":"Marquez","year":"2016","journal-title":"Pediatr Infect Dis J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.5588\/ijtld.11.0821","article-title":"High tuberculosis exposure among neonates in a high tuberculosis and human immunodeficiency virus burden setting","volume":"16","author":"Bekker","year":"2012","journal-title":"Int J Tuberc Lung Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/adc.2004.070466","article-title":"Outcome of HIV infected children with culture confirmed tuberculosis","volume":"90","author":"Hesseling","year":"2005","journal-title":"Arch Dis Child."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2431-8-1","article-title":"Clinical presentation and outcome of Tuberculosis in Human Immunodeficiency Virus infected children on anti-retroviral therapy","volume":"8","author":"Walters","year":"2008","journal-title":"BMC Pediatr."},{"key":"B29","first-page":"862","article-title":"HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort","volume":"13","author":"Martinson","year":"2009","journal-title":"Int J Tuberc Lung Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa0800971","article-title":"Early antiretroviral therapy and mortality among HIV-infected infants","volume":"359","author":"Violari","year":"2008","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3310\/hta21390","article-title":"Observational study to estimate the changes in the effectiveness of bacillus calmette-gu\u00e9rin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK","volume":"21","author":"Mangtani","year":"2017","journal-title":"Health Technol Assess."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1016\/j.vaccine.2011.05.023","article-title":"Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial","volume":"29","author":"Barreto","year":"2011","journal-title":"Vaccine."},{"key":"B34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med."},{"key":"B35","first-page":"201","article-title":"BCG Vaccines: WHO Position Paper","year":"2018","journal-title":"Weekly Epidemiological Record Relev\u00e9 \u00c9pid\u00e9miologique Hebdomadaire."},{"key":"B36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.5588\/ijtld.14.0608","article-title":"Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination","volume":"19","author":"Hesseling","year":"2015","journal-title":"Int J Tuberc Lung Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(14)70033-5","article-title":"Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review","volume":"2","author":"Kaufmann","year":"2014","journal-title":"Lancet Respir Med."},{"key":"B38","first-page":"392","article-title":"The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era B","volume":"8","author":"Marais","year":"2004","journal-title":"Int J Tuberc Lung Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2016.00310","article-title":"Linking susceptibility to infectious diseases to immune system abnormalities among HIV-exposed uninfected infants","volume":"7","author":"Ruck","year":"2016","journal-title":"Front Immunol."},{"key":"B40","year":"2018","journal-title":"Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management"},{"key":"B41","year":"2015","journal-title":"Guidelines on the Management of Latent Tuberculosis Infection"},{"key":"B42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/INF.0000000000001350","article-title":"Quantiferon-TB gold in-tube improves tuberculosis diagnosis in children","volume":"36","author":"Petrucci","year":"2017","journal-title":"Pediatr Infect Dis J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1350","DOI":"10.1542\/peds.2006-0519","article-title":"A refined symptom-based approach to diagnose pulmonary tuberculosis in children","volume":"118","author":"Marais","year":"2006","journal-title":"Pediatrics."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e2624","DOI":"10.1371\/journal.pone.0002624","article-title":"A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children","volume":"3","author":"Connell","year":"2008","journal-title":"PLoS ONE."},{"key":"B45","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1164\/rccm.201406-1165OC","article-title":"Optimizing the detection of recent tuberculosis infection in children in a high tuberculosis-HIV burden setting","volume":"191","author":"Mandalakas","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijid.2016.12.015","article-title":"Improving access to tuberculosis preventive therapy and treatment for children","volume":"56","author":"Marais","year":"2017","journal-title":"Int J Infect Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and Isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS."},{"key":"B49","doi-asserted-by":"publisher","first-page":"844","DOI":"10.5588\/ijtld.18.0122","article-title":"Value of chest X-ray in TB diagnosis in HIV-infected children living in resource-limited countries: the ANRS 12229-PAANTHER 01 study","volume":"22","author":"Berteloot","year":"2018","journal-title":"Int J Tuberc Lung Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.crad.2017.01.008","article-title":"Evaluation of a chest radiograph reading and recording system for tuberculosis in a HIV-positive cohort","volume":"72","author":"Kosack","year":"2017","journal-title":"Clin Radiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12879-017-2388-7","article-title":"Digital CXR with computer aided diagnosis versus symptom screen to define presumptive tuberculosis among household contacts and impact on tuberculosis diagnosis","volume":"17","author":"Muyoyeta","year":"2017","journal-title":"BMC Infect Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e00812","DOI":"10.1128\/mBio.00812-17","article-title":"The new Xpert MTB\/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing","volume":"8","author":"Chakravorty","year":"2017","journal-title":"mBio."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1097\/INF.0000000000001960","article-title":"Accuracy of Xpert MTB\/RIF Ultra for the diagnosis of pulmonary tuberculosis in children","volume":"37","author":"Nicol","year":"2018","journal-title":"Pediatr Infect Dis J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1128\/JCM.01771-16","article-title":"Detection of isoniazid-, fluoroquinolone-, amikacin-, and kanamycin-resistant tuberculosis in an automated, multiplexed 10-color assay suitable for point-of-care use","volume":"55","author":"Chakravorty","year":"2017","journal-title":"J Clin Microbiol."},{"key":"B55","year":"2006","journal-title":"Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e5140","DOI":"10.1371\/journal.pone.0005140","article-title":"Multiple sampling in one day to optimize smear microscopy in children with tuberculosis in Yemen","volume":"4","author":"Al-Aghbari","year":"2009","journal-title":"PLoS ONE."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1128\/JCM.00801-17","article-title":"Stool culture for the diagnosis of pulmonary tuberculosis in children","volume":"55","author":"Walters","year":"2017","journal-title":"J Clin Microbiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/cit230","article-title":"Xpert MTB\/RIF testing of stool samples for the diagnosis of pulmonary tuberculosis in children","volume":"57","author":"Nicol","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/INF.0000000000001563","article-title":"Xpert MTB\/RIF on stool is useful for the rapid diagnosis of tuberculosis in young children with severe pulmonary disease","volume":"36","author":"Walters","year":"2017","journal-title":"Pediatr Infect Dis J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fgene.2018.00457","article-title":"Meta-analysis identification of highly robust and differential immune-metabolic signatures of systemic host response to acute and latent tuberculosis in children and adults","volume":"9","author":"Bah","year":"2018","journal-title":"Front Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5588\/ijtld.17.0721","article-title":"Multicenter study of QuantiFERON\u00ae-TB gold plus in patients with active tuberculosis","volume":"22","author":"Horne","year":"2018","journal-title":"Int J Tuberc Lung Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1371\/journal.pmed.0050176","article-title":"Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens","volume":"5","author":"Burman","year":"2008","journal-title":"PLoS Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"12","author":"Kearns","year":"2003","journal-title":"N Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/clpt.1991.117","article-title":"Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine","volume":"50","author":"Crom","year":"1991","journal-title":"Clin Pharmacol Ther."},{"key":"B65","year":"2010","journal-title":"Rapid Advice: Treatment of Tuberculosis Infection in Children"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1128\/AAC.05429-11","article-title":"Pharmacokinetics of isoniazid, rifampin,and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations","volume":"55","author":"Thee","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B67","year":"2016","journal-title":"Technical Step Process to Switch to New Paediatric Tuberculosis Formulations"},{"key":"B68","year":"2017","journal-title":"FDC for TB Treatment in Children"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0716-8","article-title":"A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs","author":"Daskapan","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis\u2014advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"Wallis","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B71","year":"2017","journal-title":"Treatment of Tuberculosis: Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care"},{"key":"B72","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/INF.0000000000001069","article-title":"Low Serum concentrations of rifampicin and pyrazinamide associated with poor treatment outcomes in children with tuberculosis related to HIV status","volume":"35","author":"Ramachandran","year":"2016","journal-title":"Pediatr Infect Dis J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13063-018-2608-5","article-title":"Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial","volume":"19","author":"Chabala","year":"2018","journal-title":"Trials."},{"key":"B74","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/QAI.0b013e31819c33a3","article-title":"Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis","volume":"47","author":"Ren","year":"2008","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B75","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/QAD.0000000000001463","article-title":"CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection","volume":"31","author":"Moore","year":"2017","journal-title":"AIDS."},{"key":"B77","first-page":"171","year":"2006","journal-title":"Antiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings: Towards Universal Access. Recommendations for a Public Health Approach."},{"key":"B78","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","article-title":"Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis","volume":"28","author":"Ribera","year":"2001","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B79","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jac\/dkm484","article-title":"Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis","volume":"61","author":"Cohen","year":"2008","journal-title":"J Antimicrob Chemother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/QAD.0b013e3283550e20","article-title":"Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment","volume":"26","author":"Oudijk","year":"2012","journal-title":"AIDS."},{"key":"B81","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/01.qai.0000214808.75594.73","article-title":"Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration","volume":"42","author":"Ramachandran","year":"2006","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa1113249","article-title":"Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children","volume":"366","author":"Violari","year":"2012","journal-title":"N Engl J Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S2352-3018(18)30293-5","article-title":"Lopinavir\u2013ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir\u2013ritonavir without rifampicin: a pharmacokinetic modelling and clinical study","volume":"6","author":"Rabie","year":"2018","journal-title":"Lancet HIV."},{"key":"B84","unstructured":"\u20184-in-1' LPV\/r\/ABC\/3TC \u2013 DNDi."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","author":"La Porte","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"B86","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3851\/IMP1915","article-title":"Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children","volume":"17","author":"Zhang","year":"2012","journal-title":"Antivir Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3851\/IMP1757","article-title":"Lopinavir exposure is insufficient in children given double doses of lopinavir\/ritonavir during rifampicin-based treatment for tuberculosis","volume":"16","author":"McIlleron","year":"2011","journal-title":"Antivir Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers","volume":"69","author":"Weiner","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"B90","first-page":"233","article-title":"Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir PKs","author":"Farenc","year":"","journal-title":"Conference"},{"key":"B91","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/COH.0000000000000376","article-title":"Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings","volume":"12","author":"Maartens","year":"2017","journal-title":"Curr Opin HIV AIDS."},{"key":"B92","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","article-title":"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial","volume":"14","author":"Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S1473-3099(14)70977-6","article-title":"Raltegravir and rifampicin in patients with HIV and tuberculosis","volume":"14","author":"Klis","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"B94","article-title":"Safety and efficacy of dolutegravir-based ART in TB\/HIV co-infected adults at week 48. Oral abstract TUAB0206","author":"Dooley","year":"","journal-title":"AIDS 2018."},{"key":"B95","first-page":"378s","article-title":"P1101: PhaseI\/II study of raltegravir containing in HIV-TB cotreated children","volume":"26","author":"Meyers","year":"2018","journal-title":"Top Antivir Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1473-3099(16)30132-3","article-title":"Global burden of drug-resistant tuberculosis in children: a mathematical modelling study","volume":"16","author":"Dodd","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(15)00458-0","article-title":"Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis","volume":"3","author":"Kendall","year":"2015","journal-title":"Lancet Respir Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s12879-017-2806-x","article-title":"The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study","volume":"17","author":"Golla","year":"2017","journal-title":"BMC Infect Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e1001843","DOI":"10.1371\/journal.pmed.1001843","article-title":"Transmission of multidrug-resistant and drug-susceptible tuberculosis within households: a prospective cohort study","volume":"12","author":"Soto","year":"2015","journal-title":"PLoS Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"782","DOI":"10.5588\/ijtld.09.0327","article-title":"Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases","volume":"15","author":"Radhakrishnan","year":"2011","journal-title":"Int J Tuberc Lung Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"969","DOI":"10.5588\/ijtld.15.0123","article-title":"Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis","volume":"19","author":"Isaakidis","year":"2015","journal-title":"Int J Tuberc Lung Dis."},{"key":"B102","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S1473-3099(12)70033-6","article-title":"Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Ettehad","year":"2012","journal-title":"Lancet Infect Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/cid\/ciw489","article-title":"Baseline predictors of treatment outcomes in children with multidrug-resistant tuberculosis: a retrospective cohort study","volume":"63","author":"Chiang","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002591","article-title":"Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis","volume":"15","author":"Harausz","year":"2018","journal-title":"PLoS Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u201c9-month Bangladesh regimen\u201d for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"M Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis."},{"key":"B107","first-page":"56","year":"2016","journal-title":"Global Tuberculosis Programme. WHO Treatment Guidelines for Drug-Resistant Tuberculosis: 2016 Update."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/INF.0000000000002087","article-title":"Treatment of multidrug-resistant tuberculosis infection in children","volume":"37","author":"Cruz","year":"2018","journal-title":"Pediatr Infect Dis J."},{"key":"B109","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/00005792-200205000-00005","article-title":"Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy","volume":"81","author":"Shelburne","year":"2002","journal-title":"Medicine."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/QAD.0b013e32832afefc","article-title":"Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy","volume":"23","author":"Smith","year":"2009","journal-title":"AIDS."},{"key":"B111","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/tropej\/fmp141","article-title":"Paradoxical tuberculosis associated immune reconstitution inflammatory syndrome presenting with chylous ascites and chylothorax in a HIV-1 infected child","volume":"56","author":"Rabie","year":"2010","journal-title":"J Trop Pediatr."},{"key":"B112","first-page":"417","article-title":"Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children","volume":"11","author":"Zampoli","year":"2007","journal-title":"Int J Tuberc Lung Dis."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.5588\/ijtld.10.0721","article-title":"Early antiretroviral treatment reduces risk of bacille Calmette- Gu\u00e9rin immune reconstitution adenitis","volume":"15","author":"Rabie","year":"2011","journal-title":"Int J Tuberc Lung Dis."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2019.00159\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T05:20:40Z","timestamp":1583731240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2019.00159\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":113,"alternative-id":["10.3389\/fped.2019.00159"],"URL":"https:\/\/doi.org\/10.3389\/fped.2019.00159","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,25]]},"article-number":"159"}}